Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ekso Bionics Holdings (EKSO) over the last 13 years, with Q3 2025 value amounting to $234000.0.

  • Ekso Bionics Holdings' Share-based Compensation fell 4236.45% to $234000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $998000.0, marking a year-over-year decrease of 3544.63%. This contributed to the annual value of $1.4 million for FY2024, which is 2610.33% down from last year.
  • Ekso Bionics Holdings' Share-based Compensation amounted to $234000.0 in Q3 2025, which was down 4236.45% from $207000.0 recorded in Q2 2025.
  • Over the past 5 years, Ekso Bionics Holdings' Share-based Compensation peaked at $928000.0 during Q4 2022, and registered a low of $207000.0 during Q2 2025.
  • For the 5-year period, Ekso Bionics Holdings' Share-based Compensation averaged around $463052.6, with its median value being $441000.0 (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 4016.85% in 2022, then crashed by 4838.36% in 2023.
  • Ekso Bionics Holdings' Share-based Compensation (Quarter) stood at $791000.0 in 2021, then increased by 17.32% to $928000.0 in 2022, then crashed by 48.38% to $479000.0 in 2023, then crashed by 35.91% to $307000.0 in 2024, then fell by 23.78% to $234000.0 in 2025.
  • Its Share-based Compensation stands at $234000.0 for Q3 2025, versus $207000.0 for Q2 2025 and $250000.0 for Q1 2025.